معدلات البقيا عند مرضى سرطان الموثة المتقدم المعالجين باستئصال الخصيتين مع مضاد اندروجين دراسة مقارنة مع الأدب الطبي

The trial was performed in Al-assad University Hospital and included 67 patients with advanced prostate cancer. The age was between 50–89 years (range71 years). The patients were treated with orchidectomy and antiandrogen {ciproteronacetat}. PSA values ranged between 60ng/ml and 300ng/ml and averagely 119 ng/ml. In 60% of patients the PSA was between 100 ng/dl and 149 ng/ml. Clinically, the stage was T3b in 64% and T3a in 36%. According to finger-guided biopsy, the grade was poor G3 in 81% and intermediate G2 in 19%. We discovered bony metastasis in 27% at diagnosis. The survival rate in our study for 2, 4, 5 years was 31%, 12% and 7% respectively. In the universal studies which have performed Orchidectomy with or without antiandrogen drug, the rate was 56%, 22% and 4% respectively with flutamid while it was 55%, 19% and 3% respectively with placebo.